


Q3 & YTD 2026 Highlights




"Our outstanding performance in the first nine months of 2026 is driven by the strength of our core portfolio and continued growth of Somatuline. This momentum, combined with disciplined execution, supports our further upgraded sales and margin guidance for the year. Looking ahead, we are excited by the significant opportunities emerging from Dysport in EM & CM and Iqirvo, with a potential label update in PBC. We also look forward to the Ph.III readout of navtemadlin in myelofibrosis next year. Together with potravitug in post-transplant nephropathy, these differentiated late-stage assets underscore our ambition to bring forward new medicines with blockbuster potential and make a meaningful difference for patients."

David Loew, Chief Executive Officer

YTD sales growth¹ by key medicine



Geography breakdown



Portfolio progression

- ▶ Dysport[®]: Regulatory submission underway in EM & CM
- ▶ Iqirvo[®]: ELSPIRE regulatory submission underway for PBC label update
- ▶ Navtemadlin: Ongoing Phase III; Kartos Therapeutics integration
- ▶ Potravitug: Phase II/III initiation; Memo Therapeutics integration

Financial performance

- ▶ Q3 and YTD sales growth of +26.7% and +24.6% respectively at CER¹
- ▶ Upgraded 2026 guidance³:
 - Total sales growth⁴ ~ +23.0%
 - Core operating margin ~ 39.0% of total sales